Loading...

Home
Stock
GILD

GILD Overview

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

Loading chart...

High

131.050

Open

130.150

VWAP

129.98

Vol

5.18M

Mkt Cap

160.99B

Low

129.220

Amount

673.59M

EV/EBITDA(TTM)

11.94

Total Shares

1.24B

EV

175.33B

EV/OCF(TTM)

16.23

P/S(TTM)

5.46

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada for PrEP, and others. It also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. It has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. It operates in over 35 countries worldwide.

Show More

Events Timeline

(ET)

2026-05-07

19:50:00

Akamai Shares Rise 26.5% After Earnings

2026-05-07

16:10:00

Company Lowers 2026 EPS Guidance by Approximately $9.50

2026-05-07

16:10:00

Company Reports Q1 Revenue of $6.96B

2026-05-07

14:50:00

Notable Companies Earnings Consensus: Gilead $1.91

2026-04-29 (ET)

2026-04-29

08:40:00

Gilead Sciences' HIV Drug Application Accepted by FDA

2026-04-28 (ET)

2026-04-28

08:50:00

Gilead Completes Acquisition of Arcellx for Approximately $7.8 Billion

News

CNBC

Bristol Myers Squibb Partners with Hengrui Pharma for Drug Development

Significant Partnership: Bristol Myers Squibb has announced a potential multi-billion dollar partnership with Hengrui Pharma, aiming to co-develop around a dozen drugs, including four that Bristol will send to China for early-stage clinical trials, marking a new phase of international collaboration in drug development.
Shift in R&D Model: This collaboration represents a departure from traditional licensing agreements, as both companies will contribute resources to drug development, positioning China as a vital part of the global pharmaceutical R&D ecosystem and highlighting U.S. drugmakers' increasing focus on the Chinese market.
Market Trend Shift: According to DealForma, over half of large pharmaceutical licensing deals this year have originated from China, up from 39% last year, indicating a growing trend among U.S. and European biopharmaceutical companies to shift early drug development to China to expedite market entry.
Future Industry Outlook: Experts predict that early-stage drug discovery will increasingly move to China due to its ability to conduct studies at lower costs and faster timelines, potentially reshaping the U.S. pharmaceutical landscape and encouraging more companies to initiate early clinical trials in China.

seekingalpha

05-15seekingalpha

Gilead Sciences Prices $3 Billion Senior Notes Offering

Bond Offering Size: Gilead Sciences announced a public offering of senior unsecured notes totaling $3 billion, which includes $500 million of 4.250% notes maturing in 2028, $1 billion of 4.400% notes maturing in 2029, $1 billion of 4.600% notes maturing in 2031, and $500 million of 4.900% notes maturing in 2034, demonstrating the company's strong capital market financing capabilities.
Use of Proceeds: The funds raised from this bond issuance will be allocated for general corporate purposes, including acquisitions, investments, strategic transactions, or other business opportunities, indicating Gilead's proactive strategy to expand its business and enhance market competitiveness.
Issuance Timeline: The bond offering is expected to close on May 20, 2026, pending standard conditions, providing investors with a clear expectation of cash inflow and helping to boost market confidence.
Market Reaction Outlook: Gilead's bond issuance is likely to attract investor interest in the current market environment, particularly against the backdrop of the biopharmaceutical industry seeking funding support, which is expected to positively impact the company's financial position.

Newsfilter

05-15Newsfilter

Gilead Sciences Prices $3 Billion Senior Unsecured Notes Offering

Bond Offering Size: Gilead Sciences announced the pricing of $3 billion in senior unsecured notes, which includes $500 million of 4.250% notes maturing in 2028, $1 billion of 4.400% notes maturing in 2029, $1 billion of 4.600% notes maturing in 2031, and $500 million of 4.900% notes maturing in 2034, reflecting the company's robust capital market financing capabilities.
Clear Use of Proceeds: The net proceeds from this bond offering will be used for general corporate purposes, including potential acquisitions, investments, and other strategic transactions, indicating Gilead's proactive approach to expanding its business and seizing new opportunities.
Strong Underwriter Lineup: Barclays Capital, BofA Securities, and Citigroup Global Markets are acting as lead underwriters for this offering, enhancing market confidence in the bonds while providing strong market support for the company.
Compliance and Transparency: The offering complies with SEC registration requirements, with all related documents available for free on the SEC's website, ensuring that investors can fully understand the investment risks and related information, demonstrating the company's commitment to compliance and transparency.

Newsfilter

05-13Newsfilter

Gilead Presents New Data at EASL Congress on Livdelzi and Bulevirtide

Livdelzi Clinical Data: Gilead presented randomized and long-term study data for Livdelzi (seladelpar) in primary biliary cholangitis (PBC) patients at EASL, demonstrating its efficacy in reducing ALP levels, which may enhance patient quality of life and has significant clinical implications.
HDV Research Progress: Gilead showcased clinical data on bulevirtide for HDV co-infection in chronic hepatitis B patients, emphasizing its safety and tolerability across diverse HDV patient populations, reflecting the company's ongoing leadership in HDV treatment.
HCV Elimination Efforts: The company also highlighted progress in hepatitis C elimination research, particularly a 7-year outcome study in prisons, indicating its positive contributions to public health and potential influence on future policy-making.
Future Research Directions: Gilead's studies include a machine learning model to identify risk factors for liver disease progression in HDV-infected patients, showcasing the company's innovative potential in leveraging new technologies for liver disease management.

CNBC

Fluence Energy Shares Soar Nearly 30% After Upgrades

Fluence Energy Surge: Fluence Energy's stock soared nearly 30% after its fiscal second-quarter EBITDA exceeded Wall Street estimates, following a prior session surge of about 40%, indicating strong market confidence in its growth potential and attracting more investor interest.
Corpay Raises Guidance: Corpay shares jumped 10% after the company raised its full-year earnings guidance to a range of $26.30 to $27.10 per share, surpassing analyst expectations of $26.05, reflecting robust performance in the corporate payments sector and potentially increasing market share.
Akamai Technologies Rises: Akamai's stock surged 20% after securing an $1.8 billion commitment from a leading U.S. frontier model provider for its Cloud Infrastructure Services, indicating strong demand in the market, while also reporting a first-quarter adjusted earnings beat that bolstered investor confidence.
Upwork Restructuring Impact: Upwork's shares tumbled 21% following its announcement of a 24% workforce reduction to ensure profitability, despite slightly lower-than-expected first-quarter earnings and revenue, which may affect its future competitive position and investor sentiment.

Yahoo Finance

05-08Yahoo Finance

Gilead Sciences Posts Strong Q1 2026 Performance Driven by HIV Drug Growth

Revenue Growth: Gilead Sciences reported a 4% year-on-year increase in total revenue for Q1 2026, reaching $7 billion, exceeding analyst expectations and demonstrating strong performance in the HIV drug sector.
HIV Drug Sales: Of the $6.9 billion in total product sales, the HIV portfolio contributed $5 billion, growing 10% year-on-year, with Biktarvy generating $3.36 billion, up from $3.15 billion in 2025, solidifying its market leadership.
PrEP Drug Performance: Sales of Descovy reached $807 million, a 38% increase from 2025, surpassing market expectations, while the newly launched Yeztugo achieved early success with $166 million in sales this quarter, projected to become a blockbuster product.
New Drug Development Outlook: Gilead's anitocabtagene autoleucel (anito-cel) is under FDA review, expected to generate revenue in early 2027, with analysts believing it could be a strong contender in treating multiple myeloma, potentially reshaping the market landscape.

Wall Street analysts forecast GILD stock price to rise

19 Analyst Rating

Wall Street analysts forecast GILD stock price to rise

16 Buy

3 Hold

0 Sell

Strong Buy

Current: 0.000

Low

105.00

Averages

137.88

High

154.00

Current: 0.000

Low

105.00

Averages

137.88

High

154.00

Morgan Stanley

Overweight

to

NULL

downgrade

$175 -> $168

AI Analysis

2026-05-10

Reason

Morgan Stanley

Price Target

$175 -> $168

AI Analysis

2026-05-10

downgrade

Overweight

to

NULL

Reason

Morgan Stanley lowered the firm's price target on Gilead to $168 from $175 and keeps an Overweight rating on the shares. The firm updated the company's model post the Q1 report.

Truist

Buy

maintain

$155 -> $157

2026-05-08

Reason

Truist

Price Target

$155 -> $157

2026-05-08

maintain

Buy

Reason

Truist raised the firm's price target on Gilead to $157 from $155 and keeps a Buy rating on the shares. The company delivered Q1 top- and bottom-line beats with a raised FY26 revenue guide, driven by HIV strength, particularly Yeztugo, the analyst tells investors in a research note. The firm further underscores the commentary around early persistency signals - including Yeztugo being the highest among patients receiving re-treatment in the PrEP setting - as encouraging and central to its thesis for durable Yeztugo growth toward our $7B+ peak revenue opportunity.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GILD

Unlock Now

Valuation Metrics

The current forward P/E ratio for Gilead Sciences, Inc (GILD.O) is 15.04, compared to its 5-year average forward P/E of 12.00. For a more detailed relative valuation and DCF analysis to assess Gilead Sciences, Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

12.00

Current PE

15.04

Overvalued PE

14.52

Undervalued PE

9.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

9.18

Current EV/EBITDA

11.36

Overvalued EV/EBITDA

11.20

Undervalued EV/EBITDA

7.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

3.88

Current PS

4.97

Overvalued PS

4.60

Undervalued PS

3.15

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

then do u have other alternative stock

Intellectia · 8 candidates

Market Cap: >= 5.00BThemes: BiotechAnalyst Consensus: Moderate Buy, Strong BuyMoving Average Relationship: PriceAboveMA200Is Optionable: True

Ticker

Name

Market Cap$

Amgen Inc

181.47B

Gilead Sciences, Inc

160.88B

Vertex Pharmaceuticals Inc

110.90B

Regeneron Pharmaceuticals Inc

73.20B

Biogen Inc

28.49B

Incyte Corp

19.04B

best stock to buy now

Intellectia · 43 candidates

Market Cap: >= 20.00BRegion: USVolume: >= 2,000,000Analyst Consensus: Strong BuyQuarter Eps Yoy Growth: >= 15.0%List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA20, PriceAboveMA200

Ticker

Name

Market Cap$

Alphabet Inc

4.79T

Amazon.com Inc

2.92T

Taiwan Semiconductor Manufacturing Co Ltd

2.15T

Broadcom Inc

1.95T

Eli Lilly and Co

918.16B

Micron Technology Inc

729.23B

best stock to buy

Intellectia · 24 candidates

Region: USQuarter Revenue Yoy Growth: >= 0.0%Market Cap Category: large, megaAnalyst Consensus: Strong BuyQuarter Eps Yoy Growth: >= 0.0%Net Margin: >= 10.00Pe Ttm: <= 30Return On Equity: >= 10.0%Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Ev Ebitda: <= 20

Ticker

Name

Market Cap$

AstraZeneca PLC

283.06B

SAP SE

203.98B

Gilead Sciences, Inc

166.40B

Newmont Corporation

121.16B

Intuit Inc

112.50B

Freeport-McMoRan Inc

87.11B

option with low spread for today

Intellectia · 192 candidates

Price: $20.00 - $500.00Market Cap Category: large, midRelative Vol: >= 1Is Optionable: TrueOption Iv Rank: 20 - 60Is Index Component: GSPC, NDX, DJI, RUT

Ticker

Name

Market Cap$

Nextera Energy Inc

194.60B

Walt Disney Co

188.69B

Boeing Co

182.12B

Arista Networks Inc

178.49B

Thermo Fisher Scientific Inc

176.32B

AT&T Inc

175.52B

Intellectia · 341 candidates

Region: USMarket Cap Category: largeRelative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Is Index Component: GSPC, RUT, DJI, NDX

Ticker

Name

Market Cap$

Nextera Energy Inc

198.92B

Verizon Communications Inc

198.09B

Walt Disney Co

187.65B

Boeing Co

181.25B

Amgen Inc

178.70B

Seagate Technology Holdings PLC

176.34B

cue today projection and buy and sell

Intellectia · 2 candidates

Themes: BiotechRsi Category: moderateRelative Vol: >= 1List Exchange: XNASMoving Average Relationship: PriceAboveMA5Is Optionable: TrueNews Driver: Positive

Ticker

Name

Market Cap$

Illumina Inc

19.25B

Gilead Sciences Inc

162.40B

best left to buy now

Intellectia · 85 candidates

Analyst Consensus: Strong Buy, Moderate BuyEps 5yr Cagr: >= 5Pe Ttm: 8 - 35Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC, NDX

Ticker

Name

Market Cap$

Alphabet Inc

4.14T

Apple Inc

3.98T

JPMorgan Chase & Co

826.87B

Micron Technology Inc

560.17B

Johnson & Johnson

547.64B

Bank of America Corp

371.11B

show top 15 stocks for 5-10 years

Intellectia · 30 candidates

Market Cap: >= 50.00BRegion: USMarket Cap Category: mega, largeEps 5yr Cagr: >= 12Pe Ttm: 12 - 30List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 15.0%

Ticker

Name

Market Cap$

Mastercard Inc

449.63B

Visa Inc

589.76B

Netflix Inc

389.25B

Aon PLC

68.81B

Ferrari NV

82.27B

Gilead Sciences Inc

161.86B

good stocks for options trading

Intellectia · 29 candidates

Market Cap: >= 50.00BList Exchange: XNAS, XNYS, XASEIs Optionable: TrueOption Iv Rank: 25 - 75Is Index Component: NDXMonthly Average Dollar Volume: >= 10,000,000

Ticker

Name

Market Cap$

NVIDIA Corp

4.85T

Comcast Corp

113.84B

Amazon.com Inc

2.74T

Apple Inc

4.01T

CSX Corp

85.79B

Texas Instruments Inc

256.83B

what stock should buy

Intellectia · 96 candidates

Market Cap: >= 10.00BQuarter Eps Yoy Growth: >= 5.0%Pe Ttm: 10 - 35Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

Alphabet Inc

4.11T

Apple Inc

3.97T

Amazon.com Inc

2.69T

JPMorgan Chase & Co

832.27B

Micron Technology Inc

513.20B

Bank of America Corp

384.37B

Whales Holding GILD

Mubadala Investment Company PJSC

ProFund Advisors LLC

Caxton Associates (USA) LLC

Brevan Howard Capital Management LP

Keskinäinen vakuutusyhtiö Eläke-Fennia

Pacific Investment Management Company LLC

Trading Trends

Insider

Hedge Fund

Congress Trading

People Also Watch

Frequently Asked Questions

What is Gilead Sciences, Inc (GILD) stock price today?

The current price of GILD is 129.67 USD — it has increased 0.07

What is Gilead Sciences, Inc (GILD)'s business?

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada for PrEP, and others. It also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. It has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. It operates in over 35 countries worldwide.

What is the price predicton of GILD Stock?

Wall Street analysts forecast GILD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GILD is137.88 USD with a low forecast of 105.00 USD and a high forecast of 154.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Gilead Sciences, Inc (GILD)'s revenue for the last quarter?

Gilead Sciences, Inc revenue for the last quarter amounts to 6.96B USD, increased 4.39

What is Gilead Sciences, Inc (GILD)'s earnings per share (EPS) for the last quarter?

Gilead Sciences, Inc. EPS for the last quarter amounts to 1.61 USD, increased 54.81

How many employees does Gilead Sciences, Inc (GILD). have?

Gilead Sciences, Inc (GILD) has 17000 emplpoyees as of May 19 2026.

What is Gilead Sciences, Inc (GILD) market cap?

Today GILD has the market capitalization of 160.99B USD.